Abstract

**Background:** A reduction in adiposity may be associated with an improvement in insulin sensitivity and β-cell function as well as cardiovascular disease (CVD) risk factors; however, few studies have investigated these associations in a longitudinal setting.

**Methods:** To investigate these associations over a 1-year period, we conducted an observational analysis of 196 Japanese subjects with obesity in the Saku Control Obesity Program. We investigated the relations between changes in adiposity (body mass index [BMI], waist circumference, subcutaneous fat area [SFAT], and visceral fat area [VFAT]) and changes in HbA1c, fasting plasma glucose (FPG), insulin sensitivity index (ISI), the homeostasis model assessment β cell function (HOMA-β), lipids, and blood pressure.

**Results:** All adiposity changes were positively associated with HbA1c and FPG changes. Reductions in BMI and VFAT were associated with HOMA-β reduction. Reductions in all adiposity measures were associated with an improvement in the ISI. Changes in most adiposity measures were positively associated with changes in blood pressure and lipid levels, except for LDL.

**Conclusion:** The present findings provide additional supportive evidence indicating that a reduction in adiposity may lead to an improvement in insulin sensitivity and the reduction of CVD risk factors in obese individuals.
changes in adiposity and insulin resistance or β-cell function has not been well-understood.

Therefore, we investigated the associations between changes in adiposity, including SFAT and VFAT evaluated using computed tomography, and changes in insulin secretion and sensitivity as well as CVD risk factors in 196 Japanese participants with obesity over a 1-year period.

Materials and Methods

Ethics statement

This study was reviewed and approved by the Ethical Committee of the National Institute of Health and Nutrition and Saku Central Hospital. Participants received a precise explanation of the study and provided their written informed consent.

Subjects

This is a study of a randomized controlled trial, the Saku Control Obesity Program (SCOP), examining the effect of behavioral treatment and exercise at the Saku Central Hospital Human Dock Center. The details and design of the study have been previously described elsewhere [12] treatment at the Saku Health Dock Center. People who had undergone health checkups at the center were registered in the database, and 976 members between the ages of 40 and 64 years who did not have type 1 diabetes or severe diseases, such as stroke, cardiovascular disease, advanced cancer or significant renal or hepatic dysfunction, and had a body mass index (BMI) in the upper five percentile of all examinees (28.3 or above) were invited. A total of 237 people participated in the study and were randomly assigned to two groups: group A, who participated in a lifestyle intervention program during year 1; and group B, who participated in the same intervention program during year 2. The intervention group received individual-based counseling on diet and physical activity, and by 1 year, the intervention group had significantly lost more weight than the control group (−5.0 kg vs. 0.1 kg among men, \(P < 0.01\); −2.9 kg vs. −0.2 kg among women, \(P < 0.01\)) [15].

In this study, we excluded 29 patients who had already been diagnosed as having diabetes and were receiving treatment at baseline or at 1 year (27 participants and 2 participants, respectively), 3 participants not in fasting states at the time of blood sampling, and 9 participants who did not complete the study. Finally, 196 participants were included in the analysis.

Anthropometric Measurements

The height (cm) and weight (kg) of the subjects were measured using an automatic scale (BF-220; Tanita, Tokyo, Japan), and the BMI was calculated as the weight (kg) divided by the squared height (m²). The waist circumference was measured twice in a standing position at the umbilicus level using a fiber glass measuring tape, and the average was used for the analysis. Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (HEM-907; Omron, Kyoto, Japan) [16].

The VFAT and SFAT were assessed based on a CT scan at the level of the umbilicus while the subject was in a supine position (Fat scan; N2 system Corp., Japan) [6]. Physical activity levels were obtained from a questionnaire that aimed to identify activity levels during the recent month as follows: light activity, approximately 1 hour of walking or 3 hours of standing per day; medium activity, approximately 2 hours of walking or 6 to 7 hours of standing per day; moderately-to-heavy activity, approximately 1 hour of intense activity plus 9 hours of walking or standing per day; heavy activity, approximately 2 hours of intense activity plus 9 hours of walking or standing per day.

Laboratory Procedures

Following an overnight fast, blood samples were collected at the time of each health checkup at the Saku Health Dock Center. Blood samples were collected in tubes containing EDTA and heparin for the measurement of fasting plasma glucose (FPG), insulin, and HbA1c and in serum gel separator tubes for the measurement of total cholesterol, high-density lipoprotein cholesterol (HDL), and triglyceride (TG) levels. Routine laboratory blood analyses were performed at the Saku Central Hospital. HbA1c levels were measured using a high-performance liquid chromatography method (TOSOH HLC-723 G8, Tosoh Corporation, Tokyo, Japan) with intra- and inter-assay coefficients of variation (CVs) ≤1.4%. The plasma glucose levels were analyzed using an enzymatic method (ECO glucose buffer; A&K Corporation, Kanagawa, Japan), with intra- and inter-assay CVs ≤0.8%. The plasma insulin levels were analyzed using an electrochemiluminescence immunnoassay (Modular E170; Roche Diagnostics, Mannheim, Germany) with intra- and inter-assay CVs ≤3.6%. The serum total cholesterol, HDL, and TG concentrations were determined using enzymatic methods (Detaminar L TC II, Kyowa Medex, Tokyo, Japan; Cholestest N HDL, Sekisui Medical Co Ltd, Tokyo, Japan; and Mizuho TG-FR Type II, Mizuho Medi, Saga, Japan, respectively) and an autoanalyzer BM-2250 (Nikon Densihi, Tokyo, Japan) with intra- and inter-assay CVs of ≤2.3%. The HbA1c values were determined as Japan Diabetes Society (JDS) values and then converted to National Glycohemoglobin Standardization Program (NGSP) values using the following conversion formula: HbA1c (NGSP) = 1.02 × HbA1c (JDS)+0.25% [17]. The low-density lipoprotein cholesterol levels (LDL) were calculated using the Friedewald equation: \(LDL = total\ cholesterol - HDL + (TG/5)\).

To evaluate insulin sensitivity, we used the homeostasis model assessment for insulin resistance (HOMA-IR) [18] and the insulin sensitivity index (ISI) with reduced time points [19]; to evaluate β cell function, we used the homeostasis model assessment β cell function (HOMA-β) [20] and the insuliniogenic index [21,22] based on a 75 g oral glucose tolerance test (OGTT). The HOMA-IR was calculated as follows: fasting insulin (I₀) (\(\mu\text{IU/mL}\) × fasting glucose (G₀) (mg/dL)/405. [18] We calculated the ISI using reduced time points because of the absence of 90-minute glucose-load values from the OGTTs, with the measurement of the insulin and glucose levels at 0, 60 and 120 minutes as follows: ISI = 10,000/\(\sqrt{G₀ \times I₀ \times mean\ OGTT\ glucose\ concentration \times mean\ OGTT\ insulin\ concentration}\) [23]. This index has been reported to be well correlated with the original composite index; we did not use G₀ and I₀ in our calculations because this time point was not recommended when using reduced time points to calculate the ISI [23]. The HOMA-β was calculated using the formula: \(360 \times I₀ (\mu\text{IU/mL})/G₀ (\text{mg/dL}) − 63\). The insuliniogenic index was calculated as follows: \(Iₙ₀/I₀\)\(/(Gₙ₀–G₀)\) [24].

Data analysis

The characteristics of the study population are presented as the mean for continuous variables. We calculated the means (± SDs) and the proportions of the covariates. A visual inspection of the histograms did not reveal any violations of the assumption of normality; we conducted the analysis without the use of log transformation. To compare the characteristics of the participants at baseline and at 1 year, we used a paired t test (Table 1). Then, we investigated the associations of CVD risk factors and insulin
secretion and sensitivity using adiposity measures (Tables 2, 3, 4). We used multiple linear regression models to estimate the point estimates, the 95% confidence intervals (95% CIs), and the P-values with adjustments for potential confounding factors including age, sex, baseline adiposity measures, baseline insulin related indexes, intervention group assignment, and physical activity level. In addition, we conducted the following sensitivity analyses: (i) stratification according to sex, (ii) stratification according to WHO diagnostic criteria for impaired glucose tolerance (IGT) and diabetes, and (iii) exclusion of participants with medications for hyperlipidemia. We also examined the associations with stratification according to the intervention assignment, but the direction and strength of the associations remained consistent across the subgroups. Thus, we focused primarily on the associations for the full sample (i.e., the product terms were not included in the models).

Two-sided P values <0.05 were considered to be statistically significant. Analyses were performed using Stata software (version 12; Stata Corp, College Station, TX).

Results

Among a total of 196 participants aged 40 to 64 years, the mean age was 53.8 years. At baseline, all the participants had obesity with relatively high average glucose levels accompanied by insulin resistance and hyperinsulinemia (Table 1). Over a 1-year period, reductions in all adiposity measures, HbA1c, insulin secretion, TG, and systolic blood pressure were observed, possibly because of the trial intervention (Table 1).

After adjustments for age, sex, physical activity, intervention assignment, baseline adiposity measures, and the baseline value of the outcome variable, reductions in all adiposity measures, including BMI, SFAT, VFAT, and waist circumference, were associated with reductions in the HbA1c and FPG levels (Table 2). The relations between the changes in adiposity and glucose levels were consistent with previous findings. In this study, we were able to further examine the associations of changes in adiposity with the changes in insulin secretion and resistance. As expected, reductions in BMI and VFAT were associated with an improvement in insulin sensitivity as measured using the HOMA-IR and ISI (Table 3). Furthermore, reductions in all adiposity measures were associated with an elevation in the ISI. Decreases in BMI and visceral fat area were related to reduced insulin secretion as measured using the HOMA-β. In contrast, changes in the insulinogenic index were not related to changes in any adiposity measure (Table 3).

Changes in any of the adiposity measures were not associated with the change in the LDL level, but a change in VFAT was inversely associated with a change in HDL while changes in the BMI, VFAT, and waist circumference were positively associated with a change in the TG level (Table 4). In addition, changes in the BMI, VFAT, and waist circumference were positively associated with changes in the systolic and diastolic blood pressure (Table 4).

A sensitivity analysis stratified according to sex did not substantially change the results; and furthermore, the exclusion of the participants with hyperlipidemia medications (n = 39) did not materially alter the results (data not shown). According to the WHO diagnostic criteria [25], there were 86 participants with normal glucose tolerance (NGT), 11 participants with impaired fasting glycemia (IFG), 76 participants with impaired glucose tolerance (IGT), and 23 participants with diabetes. The adiposity-HbA1c association was slightly stronger among the participants with IFG, IGT, and diabetes (n = 110), compared with those with NGT. After excluding participants with diabetes, the associations between the changes in HOMA-β and the changes in adiposity measures (e.g., VFAT) became stronger (coefficient, 0.62; 95%CI 0.31, 0.92).

Table 1. Baseline characteristics of participants.

|                      | Baseline | 1 year | P value* |
|----------------------|----------|--------|----------|
| N                    | 196      | 196    |          |
| Male/Female (n)      | 96/100   |        |          |
| Age (years)          | 53.8 ± 6.4 |        |          |
| BMI (kg/m²)          | 30.5 ± 3.1 | 29.6 ± 3.5 | < 0.001 |
| Subcutaneous fat area (cm²) | 294 ± 102 | 268 ± 94 | < 0.001 |
| Visceral fat area (cm²) | 139 ± 48 | 123 ± 47 | < 0.001 |
| Waist circumference (cm) | 102 ± 8 | 100 ± 9 | < 0.001 |
| HbA1c (%)            | 6.0 ± 0.8 | 5.8 ± 0.5 | < 0.001 |
| Fasting plasma glucose (mg/dL) | 106 ± 13 | 107 ± 14 | 0.21 |
| Fasting insulin (µU/mL) | 11.3 ± 8.0 | 9.4 ± 10.0 | 0.01 |
| HOMA-IR              | 3.0 ± 2.2 | 2.6 ± 3.3 | 0.14 |
| HOMA-β               | 100 ± 72 | 77 ± 62 | < 0.001 |
| Insulin Sensitivity Index | 4.8 ± 3.4 | 6.5 ± 4.2 | < 0.001 |
| Insulinogenic index  | 0.84 ± 0.90 | 0.91 ± 1.8 | 0.57 |
| LDL (mg/dL)          | 126 ± 34 | 128 ± 30 | 0.37 |
| HDL (mg/dL)          | 53 ± 12 | 52 ± 13 | 0.21 |
| Triglyceride (mg/dL) | 162 ± 106 | 142 ± 72 | < 0.001 |
| Systolic blood pressure (mmHg) | 138 ± 19 | 132 ± 20 | < 0.001 |
| Diastolic blood pressure (mmHg) | 85 ± 14 | 83 ± 14 | 0.07 |

Data are (n) or means ± SD. * P value for paired t test.
Abbreviations: BMI, body mass index; HOMA-IR, homeostasis model assessment ratio; HOMA-β, homeostasis model assessment β cell function.

Table 2. Associations between changes in adiposity measures and glucose indices from baseline to 1 year.

| Outcome variables | Δ HbA1c (%) | Δ FPG (mg/dL) |
|-------------------|-------------|---------------|
| Coef.             | P value     | Coef.         | P value |
| Explanatory variables (95% CL) (95% CL) | (95% CL) (95% CL) |
| Δ BMI (kg/m²)     | 0.09        | <0.001        | 1.90     | 0.001 |
|                   | (0.05, 0.12) | (0.79, 3.02)  |          |
| Δ Subcutaneous fat area (cm²) | 0.003 | <0.001 | 0.07 | 0.003 |
|                   | (0.02, 0.005) | (0.03, 0.12)  |          |
| Δ Visceral fat area (cm²) | 0.005 | <0.001 | 0.08 | 0.01 |
|                   | (0.003, 0.007) | (0.02, 0.14)  |          |
| Δ Waist circumference (cm) | 0.03 | <0.001 | 0.48 | 0.01 |
|                   | (0.01, 0.04) | (0.11, 0.86)  |          |

Abbreviations: BMI, body mass index; FPG, fasting plasma glucose; Coef., coefficient; CL, confidence limit.
In this prospective study, changes in all the examined adiposity measures were positively associated with changes in glycemia in 196 Japanese participants with obesity. Furthermore, we found that reductions in BMI, visceral fat area, and waist circumference were associated with a reduction in HOMA-\(b\), while no association was observed for the insulinogenic index. Reductions in BMI and VFAT were also associated with an improvement in insulin sensitivity. In addition, changes in adiposity were related to changes in TG and blood pressure. These findings suggest that controlling adiposity among obese individuals may effectively improve CVD risk factors and insulin sensitivity.

These results were consistent with a preceding study among obese individuals with type 2 diabetes, in which weight loss was associated with an improvement in glycemia, blood pressure, TG, and HDL [8,9]. In the current study, we were able to assess VFAT and SFAT changes using computed tomography. We found that a reduction in visceral adiposity as well as the BMI was associated with an improvement in the CVD risk factors. Consistent with the previous study [8], the adiposity change was not associated with the LDL change in the current study. In another study reviewing weight loss effects and lipid outcomes [26], weight loss was reported to be associated with the LDL reduction. This dissociation may be because, in a previous review [26], studies with a large weight reduction (22 to 55 kg) as a result of surgical intervention were included. In the current study, the mean weight

### Table 3. Associations between changes in adiposity measures and insulin related indexes from baseline to 1 year.

| Outcome variables | \(\Delta\) Insulin (\(\mu\)IU/mL) | \(\Delta\) HOMA-IR | \(\Delta\) ISI | \(\Delta\) HOMA-\(b\) | \(\Delta\) Insulinogenic index |
|-------------------|-------------------------------|------------------|-------------|----------------|-----------------------------|
|                   | Coef. (95% CL) | Coef. (95% CL) | Coef. (95% CL) | Coef. (95% CL) | Coef. (95% CL) |
| Explanatory variables | | | | | |
| \(\Delta\) BMI (kg/m\(^2\)) | 1.09 (0.16, 2.01) | 0.32 (0.01, 0.64) | -1.05 (-1.32, -0.78) | 7.43 (2.02, 12.8) | 0.14 (-0.04, 0.31) |
| \(\Delta\) Subcutaneous fat area (cm\(^2\)) | 0.02 (-0.02, 0.06) | 0.01 (-0.01, 0.02) | -0.03 (-0.04, -0.02) | 0.12 (-0.11, 0.36) | 0.31 (-0.004, 0.39) |
| \(\Delta\) Visceral fat area (cm\(^2\)) | 0.06 (0.01, 0.11) | 0.02 (0.0001, 0.03) | -0.05 (-0.06, -0.03) | 0.50 (0.21, 0.79) | -0.0005 (-0.01, 0.009) |
| \(\Delta\) Waist circumference (cm) | 0.25 (-0.05, 0.56) | 0.07 (-0.03, 0.18) | -0.29 (-0.39, -0.20) | 1.80 (-0.02, 3.62) | 0.04 (-0.02, 0.15) |

Abbreviations: BMI, body mass index; HOMA-IR, homoeostatic model assessment for insulin resistance; ISI, insulin sensitivity index; HOMA-\(b\), homeostasis model assessment for \(b\)-cell function; Coef., coefficient; CL, confidence limit.

A multiple linear regression model was used to adjust for potential confounding factors including age, sex, physical activity levels, intervention assignment, the baseline adiposity measure of interest, and the baseline value of insulin related indexes.

doi:10.1371/journal.pone.0057964.t003

### Table 4. Associations between changes in adiposity measures and lipid levels and blood pressure from baseline to 1 year.

| Outcome variables | \(\Delta\) LDL (mg/dL) | \(\Delta\) HDL (mg/dL) | \(\Delta\) Triglyceride (mg/dL) | \(\Delta\) Systolic blood pressure (mmHg) | \(\Delta\) Diastolic blood pressure (mmHg) |
|-------------------|-----------------|-----------------|----------------------------|-----------------|-----------------|
|                   | Coef. (95% CL) | Coef. (95% CL) | Coef. (95% CL) | Coef. (95% CL) | Coef. (95% CL) |
| Explanatory variables | | | | | |
| \(\Delta\) BMI (kg/m\(^2\)) | 0.47 (-1.71, 2.66) | -0.63 (-1.28, 0.03) | 9.37 (4.75, 14.0) | 2.03 (0.47, 3.59) | 1.48 (0.35, 2.62) |
| \(\Delta\) Subcutaneous fat area (cm\(^2\)) | 0.04 (-0.05, 0.13) | -0.01 (-0.04, 0.02) | 0.19 (-0.08, -0.01) | 0.03 (-0.03, 0.32) | 0.03 (-0.02, 0.19) |
| \(\Delta\) Visceral fat area (cm\(^2\)) | -0.03 (-0.15, 0.08) | -0.05 (-0.08, -0.01) | 0.48 (0.23, 0.72) | <0.001 (0.04, 0.20) | 0.12 (0.004, 0.13) |
| \(\Delta\) Waist circumference (cm) | 0.33 (-0.38, 1.05) | -0.17 (-0.39, 0.04) | 2.61 (1.07, 4.15) | 0.001 (0.15, 1.18) | 0.66 (0.08, 0.82) |

Abbreviations: BMI, body mass index; LDL, low density cholesterol; HDL, high density cholesterol; Coef., coefficient; CL, confidence limit.

A multiple linear regression model was used to adjust for potential confounding factors including age, sex, physical activity levels, intervention assignment, the baseline adiposity measure of interest, and the baseline value of lipid levels.

doi:10.1371/journal.pone.0057964.t004
reduction within 1 year was 2.4 kg (SD 4.3), so the amount of the weight reduction may have been insufficient to detect any changes.

Among adiposity measures, changes in BMI and VFAT were positively associated with changes in insulin and HOMA-IR and were inversely associated with changes in ISI. Indeed, the change in ISI was inversely associated with changes in all the adiposity measures. These findings indicate that a reduction in adiposity may lead to an improvement in insulin sensitivity. This finding is consistent with a preceding study showing that baseline adiposity measures were inversely associated with future insulin sensitivity indices [6]. Although changes in SFAT and the waist circumference were also related to some of the insulin related indices, our findings suggest that BMI and VFAT may be better markers of adiposity in this obese population. This finding is consistent with the results of preceding studies among Japanese-Americans, which have shown that the baseline VFAT, but not the SFAT, was associated with future insulin resistance [6].

Reductions in BMI, VFAT, and waist circumference were associated with a decrease in HOMA-β. Importantly, a previous study has shown that HOMA β-cell function, another measure of β-cell function, is elevated 3–4 years before the diagnosis of diabetes, and then decreases until the time of diagnosis, indicating that a period of compensation for insulin resistance exists [27]. In our study, a reduction in adiposity was related to a reduction in insulin resistance, which was accompanied by a reduction in HOMA-β. Furthermore, the associations between the HOMA-β change and the adiposity changes became stronger after the exclusion of participants with diabetes (coefficient for ΔVFAT-ΔHOMA-β, 0.50 to 0.62). This finding may suggest that a compensatory period actually exists among obese individuals who did not develop diabetes and the adiposity reduction may reduce the needs for compensatory hyperinsulinemia.

Preceding studies have also reported that a decrease in the early-phase insulin response to glucose is a major feature of glucose tolerance among Japanese [22,28,29]. However, the change in the insulinogenic index was not related to changes in any adiposity measures in our study. This finding may suggest that the insulinogenic index may not measure compensatory hyperinsulinemia observed during the compensatory period, but might instead evaluate residual β-cell function. Thus, the null association between the insulinogenic index change and the adiposity change suggests that a reduction in adiposity may be insufficient to improve residual β-cell function.

Some limitations of the present study need to be addressed. First, participants in this study were Japanese individuals with obesity, and the sample size was limited; thus generalizability may be a problem. Second, although smoking has been reported to be related to CVD and weight reduction [2], smoking data was not available, and the analysis could not be adjusted for smoking. Third, we did not have intermediate measurements. Finally, because the follow up period was relatively short, a longer period observation period is needed to confirm the results. The major strengths of this study were the high compliance of our study participants, which enabled us to assess CVD risk factors, and the observation of adiposity changes using computed tomography over a 1-year period with few participant dropouts.

Conclusions

Our findings suggest that the reduction of obesity, especially the BMI and visceral fat area, may be associated with an improvement in CVD risk factors. Furthermore, we found that reductions in BMI and visceral adiposity were associated with a reduced HOMA-β and HOMA-IR. These findings support the notion that controlling adiposity among obese individuals may effectively improve CVD risk factors and insulin resistance.

Acknowledgments

We would like to acknowledge all SCOP members and the study participants for their participation in this research. We thank Tomoko Yasuda for her assistance.

Author Contributions

Conceived and designed the experiments: MG AM AG KD SS NA MM MN. Analyzed the data: MG AG TS. Contributed reagents/materials/analysis tools: MG AG MN. Wrote the paper: MG AG YT MN.

REFERENCES

1. Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K (1987) Central obesity and coronary heart disease in men. Lancet 1: 821–824.
2. Fujimoto WY, Leonetti DL, Bergstrom RW, Shuman WP, Wahl PW (1990) Cigarette smoking, adiposity, non-insulin-dependent diabetes, and coronary heart disease in Japanese-American men. Am J Med 89: 761–771.
3. Look ARG, Wing RR (2010) Long-term effects of a lifestyle intervention on body weight reduction within 1 year was 2.4 kg (SD 4.3), so the amount of the weight reduction may have been insufficient to detect any changes.
4. Carr DB, Utzschneider KM, Boyko EJ, Asberry PJ, Hull RL, et al. (2005) A reduced-fat diet and aerobic exercise in Japanese Americans with impaired glucose tolerance decreases intra-abdominal fat and improves insulin sensitivity but not β-cell function. Diabetes 54: 340–347.
5. Poulose MC, Despres JP, Nadeau A, Moorjani S, Prud'Homme D, et al. (1992) Visceral obesity in men. Associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes 41: 826–834.
6. Hayashi T, Boyko EJ, McNeeley MJ, Leonetti DL, Kahn SE, et al. (2008) Visceral adiposity, not abdominal subcutaneous fat area, is associated with an increase in future insulin resistance in Japanese Americans. Diabetes 57: 1269–1275.
7. Altu JB, Murphy L, Fraser DH, Johnson JA, Pi-Sunyer FX (1997) Visceral fat and race-dependent health risks in obese non-diabetic pimerougenous adults. Diabetes 46: 456–462.
8. Wing RR, Lang W, Wadden TA, Safford M, Knower WC, et al. (2011) Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals of type 2 diabetes. Diabetes Care 34: 1481–1486.
9. Matsushita Y, Nakagawa T, Yamamoto S, Takahashi Y, Yokoyama T, et al. (2012) Effect of longitudinal changes in visceral fat area and other anthropometric indices to the changes in metabolic risk factors in Japanese men: the Hitachi Health Study. Diabetes Care 35: 1139–1143.
10. Goncalves FB, Kook M, Verhagen HJ, Nissen WJ, Poldermans D (2011) Body mass index, abdominal adiposity, and cardiovascular risk. Lancet 378: 217–227, author reply 228.
11. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, et al. Trajectories of glycemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. The Lancet 373: 2215–2221.
12. Watanabe S, Morita A, Aiba N, Miyachi M, Saakii S, et al. (2007) Study Design of the Saku Control Obesity Program (SCOP). Anti-Aging Medicine 5: 13–16.
13. Morita A, Ohmori Y, Suzuki N, Ide N, Morioka M, et al. (2008) Anthropometric and Clinical Findings in Obese Japanese: The Saku Control Obesity Program (SCOP). Anti-Aging Medicine 5: 70–73.
14. Tanaka T, Morita A, Kato M, Hirai T, Mizoue T, et al. (2011) Congener-specific polychlorinated biphenyls and the prevalence of diabetes in the Saku Control Obesity Program. Endocrine journal.
15. Nakade M, Aiba N, Noda N, Morita A, Miyachi M, et al. (2012) Behavioral change during weight loss program and one-year follow-up: Saku Control Obesity Program (SCOP). In Japan. Asia Pac J Clin Nutr 21: 22–34.
16. White WB, Answar YA (2001) Evaluation of the overall efficacy of the Omron office digital blood pressure HEM-907 monitor in adults. Blood Press Monit 6: 107–110.
17. Kasahagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, et al. (2012) International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values. Journal of Diabetes Investigates 3: 39–40.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, et al. (1985) Homeostasis model assessment: insulin resistance and β-cell function from the Insulinogenic index change and the adiposity change suggests that a reduction in adiposity may be insufficient to improve residual β-cell function.
fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.

19. DeFronzo RA, Matsuda M (2010) Reduced time points to calculate the composite index. Diabetes Care 33: e93.

20. Wallace TM, Levy JC, Matthews DR (2004) Use and abuse of HOMA modeling. Diabetes Care 27: 1487–1495.

21. Kosaka K, Hagura R, Kuzuya T (1977) Insulin responses in equivocal and definite diabetes, with special reference to subjects who had mild glucose intolerance but later developed definite diabetes. Diabetes 26: 944–952.

22. Yoneda H, Ikegami H, Yamamoto Y, Yamato E, Cha T, et al. (1992) Analysis of early-phase insulin responses in nonobese subjects with mild glucose intolerance. Diabetes Care 15: 1517–1521.

23. DeFronzo RA, Matsuda M (2010) Reduced time points to calculate the composite index. Diabetes Care 33: e93.

24. Wareham NJ, Phillips DI, Byrne CD, Hales CN (1995) The 30 minute insulin incremental response in an oral glucose tolerance test as a measure of insulin secretion. Diabet Med 12: 931.

25. Alberti KG, Zimmet PZ (1998) Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 15: 539–533.

26. Poobalan A, Aucott L, Smith WC, Avenell A, Jung R, et al. (2004) Effects of weight loss in overweight/obese individuals and long-term lipid outcomes—a systematic review. Obes Rev 5: 45–56.

27. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, et al. (2009) Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet 373: 2215–2221.

28. Kosaka K, Kuzuya T, Hagura R, Yoshinaga H (1996) Insulin response to oral glucose load is consistently decreased in established non-insulin-dependent diabetes mellitus: the usefulness of decreased early insulin response as a predictor of non-insulin-dependent diabetes mellitus. Diabet Med 13: S109–119.

29. Matsumoto K, Miyake S, Yano M, Uriki Y, Yamaguchi Y, et al. (1997) Glucose tolerance, insulin secretion, and insulin sensitivity in nonobese and obese Japanese subjects. Diabetes Care 20: 1562–1568.